Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 May;84(2):309-319.
doi: 10.1007/s12020-023-03528-y. Epub 2023 Sep 23.

Gene polymorphisms and thyroid hormone signaling: implication for the treatment of hypothyroidism

Gustavo C Penna  1 , Federico Salas-Lucia  1 , Miriam O Ribeiro  2 , Antonio C Bianco  3
Affiliations
Review

Gene polymorphisms and thyroid hormone signaling: implication for the treatment of hypothyroidism

Gustavo C Penna et al. Endocrine. 2024 May.

Abstract

Introduction: Mutations and single nucleotide polymorphisms (SNPs) in the genes encoding the network of proteins involved in thyroid hormone signaling (TH) may have implications for the effectiveness of the treatment of hypothyroidism with LT4. It is conceivable that loss-of-function mutations or SNPs impair the ability of LT4 to be activated to T3, reach its targets, and ultimately resolve symptoms of hypothyroidism. Some of these patients do benefit from therapy containing LT4 and LT3.

Methods: Here, we reviewed the PubMed and examined gene mutations and SNPs in the TH cellular transporters, deiodinases, and TH receptors, along with their impact on TH signaling, and potential clinical implications.

Results: In some mechanisms, such as the Thr92Ala-DIO2 SNP, there is a compelling rationale for reduced T4 to T3 activation that limits the effectiveness of LT4 to restore euthyroidism. In other mechanisms, a potential case can be made but more studies with a larger number of individuals are needed.

Discussion/conclusion: Understanding the clinical impact of the genetic makeup of LT4-treated patients may help in the preemptive identification of those individuals that would benefit from therapy containing LT3.

Keywords: T3-signaling; deiodinase; polymorphism; thyroid; thyroxine; triiodothyronine.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest A.B. is a consultant for Abbvie, Allergan, Synthonics, Sention, and Thyron. The other authors have no relevant disclosures.

References

    1. Jonklaas J, Bianco AC, Bauer AJ, Burman KD, Cappola AR, Celi FS et al. Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. Thyroid 24(12), 1670–751 (2014) - PMC - PubMed
    1. Saravanan P, Chau WF, Roberts N, Vedhara K, Greenwood R, Dayan CM, Psychological well-being in patients on ‘adequate’ doses of l-thyroxine: results of a large, controlled community-based questionnaire study. Clin. Endocrinol 57(5), 577–85 (2002) - PubMed
    1. Wekking EM, Appelhof BC, Fliers E, Schene AH, Huyser J, Tijssen JG et al. Cognitive functioning and well-being in euthyroid patients on thyroxine replacement therapy for primary hypothyroidism. Eur. J. Endocrinol 153(6), 747–53 (2005) - PubMed
    1. Samuels MH, Schuff KG, Carlson NE, Carello P, Janowsky JS, Health status, psychological symptoms, mood, and cognition in L-thyroxine-treated hypothyroid subjects. Thyroid 17(3), 249–58 (2007) - PubMed
    1. Mentuccia D, Thomas MJ, Coppotelli G, Reinhart L, Mitchell BD, Shuldiner AR et al. The Endocrine Society’s 86th Annual Meeting New Orleans, LA, USA; 2004:P3–382.

MeSH terms

Substances